KMT2A and leukemia: Our findings demonstrate that volasertib has a stronger impact on infant MLL-AF4 and MLL-AF9 leukemia cells in contrast to adult MLLr or non-MLLr leukemia, suggesting a novel and promising treatment approach for this disease.